8-K: Arrowhead Pharmaceuticals Announces Fiscal 2024 Results and Major Strategic Partnerships, Extending Cash Runway to 2028

Arrowhead Pharmaceuticals reported its fiscal year 2024 results, highlighting significant financial deals with Sarepta Therapeutics and Sixth Street, alongside progress in its drug pipeline, notably the submission of an NDA for plozasiran.

Summary

• Arrowhead Pharmaceuticals announced its financial results for the fiscal year ending September 30, 2024.
• The company reported a net loss of $599.493 million, compared to a net loss of $205.275 million in the previous year.
• Revenue for 2024 was $3.551 million, a significant decrease from $240.735 million in 2023.
• Research and development expenses increased to $505.870 million from $353.188 million in the prior year.
• Arrowhead entered into a licensing and collaboration agreement with Sarepta Therapeutics, receiving $825 million upfront, including a $325 million equity investment.
• The company also secured a $500 million strategic financing agreement with Sixth Street.
• These financial transactions are estimated to extend Arrowhead's cash runway into 2028.
• Arrowhead submitted a New Drug Application (NDA) to the FDA for plozasiran, a potential treatment for familial chylomicronemia syndrome (FCS).
• Plozasiran received Breakthrough Therapy designation from the FDA and showed positive results in Phase 3 trials.
• The company initiated Phase 3 studies of plozasiran for severe hypertriglyceridemia and completed a Phase 1/2a clinical trial for ARO-INHBE for obesity.

Sentiment

Score: 6

Explanation: While the company reported a large net loss and decreased revenue, the significant partnerships and progress with plozasiran provide a positive outlook. The cash runway extension and potential for future milestone payments contribute to a moderately positive sentiment.

Positives

• The licensing agreement with Sarepta Therapeutics provides substantial upfront cash and potential for future milestone payments totaling approximately $10 billion.
• The strategic financing with Sixth Street provides non-dilutive capital, strengthening the company's financial position.
• Plozasiran has shown promising results in clinical trials, with significant reductions in triglycerides and a favorable safety profile.
• The Breakthrough Therapy designation for plozasiran highlights its potential to address an unmet medical need.
• Arrowhead's manufacturing facility is now qualified to support clinical trials globally, enhancing its operational capabilities.

Negatives

• The company reported a substantial net loss of $599.493 million for fiscal year 2024.
• Revenue significantly decreased to $3.551 million in 2024 from $240.735 million in 2023.
• Operating expenses increased, driven by higher research and development costs.

Risks

• The company is heavily reliant on the success of its clinical programs, particularly plozasiran.
• Regulatory approval for plozasiran is not guaranteed, and delays or rejections could impact the company's prospects.
• The company faces competition from other companies developing treatments for similar indications.
• The company's ability to achieve profitability depends on successful commercialization of its drug candidates.
• Future success depends on securing additional partnerships and collaborations.

Future Outlook

Arrowhead anticipates the potential launch of its first commercial product, plozasiran, in 2025, subject to FDA review and approval, and expects its recent financial transactions to support multiple new drug launches and extend its cash runway into 2028.

Management Comments

• Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiMTM technology.
• We have the potential to impact the lives of millions of patients in need.
• We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, more importantly, over the long-term as we seek to build a sustainable, financially sound business.
• Key events have occurred during the recent period that we see as potentially transformational for Arrowhead.
• Earlier this month, we submitted our first NDA to the U.S. FDA for investigational plozasiran, paving the way for Arrowhead to potentially launch our first commercial product in 2025, subject to FDA review and approval.
• We also took steps to meaningfully strengthen our balance sheet, including entering into a large licensing and collaboration agreement with Sarepta Therapeutics, which was announced today.
• Sarepta is an important new partner with extensive clinical, regulatory, and commercial expertise and this collaboration will help us advance and commercialize multiple promising Arrowhead-discovered drug candidates that fall outside of our current commercial focus on the cardiometabolic therapeutic area.

Industry Context

Arrowhead's focus on RNAi therapeutics places it within a growing segment of the biotechnology industry, with increasing interest in gene silencing approaches for various diseases. The partnership with Sarepta, a leader in genetic medicines, is significant within the context of a broader trend of collaborations between biotech companies to leverage expertise and resources.

Comparison to Industry Standards

• Arrowhead's net loss is not unusual for a clinical-stage biotech company, similar to Alnylam Pharmaceuticals which reported a net loss of $893 million in 2023, and Silence Therapeutics which reported a net loss of $55 million in 2023.
• The upfront payment from Sarepta is substantial compared to industry averages for licensing deals. For example, Alnylam Pharmaceuticals received a $1 billion upfront payment from Roche in 2023, and Dicerna Pharmaceuticals received a $200 million upfront payment from Novo Nordisk in 2021.
• Arrowhead's cash runway extension to 2028 is a positive indicator compared to many biotech companies that often have shorter cash runways. For example, Moderna had a cash runway into 2026 prior to their COVID vaccine, and BioNTech had a cash runway into 2025 prior to their COVID vaccine.
• The potential $10 billion in milestone payments from Sarepta is significant, comparable to other large biotech deals such as the $6 billion potential milestone payments in the 2020 collaboration between Gilead Sciences and Galapagos NV.

Stakeholder Impact

• Shareholders may benefit from the potential future success of plozasiran and other drug candidates, as well as the financial stability provided by the recent partnerships.
• Employees are likely to be impacted by the company's continued focus on research and development, with potential for growth and expansion.
• Patients with FCS and severe hypertriglyceridemia may benefit from the potential approval and commercialization of plozasiran.
• Sarepta Therapeutics and Sixth Street, as partners and investors, have a significant stake in the company's success.

Next Steps

• Arrowhead will continue to advance its clinical programs, including the Phase 3 studies of plozasiran.
• The company will work towards the potential commercial launch of plozasiran in 2025, pending FDA approval.
• Arrowhead will continue to collaborate with Sarepta Therapeutics to advance partnered drug candidates.
• The company will progress its Phase 1/2a clinical trial of ARO-INHBE for obesity.

Key Dates

Keywords

RNAi, Plozasiran, Familial Chylomicronemia Syndrome, Hypertriglyceridemia, APOC3, Sarepta Therapeutics, Sixth Street, Licensing Agreement, Strategic Financing, Clinical Trials, FDA, NDA, Breakthrough Therapy, Obesity, ARO-INHBE, Biotechnology, Pharmaceuticals